Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11058665 | 0.94 | EPHX1 (0.40) | SIGMAR1SHBGKDM4EEPHX1CYP1A2 | |
| SCHEMBL28785546 | 0.93 | SIGMAR1 (0.42) | SIGMAR1SHBGKDM4EEPHX1EPHX2 | |
| SCHEMBL24065663 | 0.91 | SIGMAR1 (0.40) | SIGMAR1KDM4EEPHX1EPHX2MEN1 | |
| SCHEMBL27818251 | 0.89 | SIGMAR1 (0.39) | SIGMAR1EPHX1CYP1A2EPHX2MEN1 | |
| SCHEMBL9885785 | 0.88 | SHBG (0.41) | SIGMAR1SHBGKDM4EEPHX1EPHX2 | |
| SCHEMBL23375445 | 0.88 | SHBG (0.41) | SIGMAR1SHBGKDM4EEPHX1EPHX2 | |
| SCHEMBL24896320 | 0.86 | SIGMAR1 (0.37) | SIGMAR1EPHX1CYP1A2EPHX2MEN1 | |
| SCHEMBL20093646 | 0.86 | EPHX1 (0.42) | SIGMAR1EPHX1CYP1A2EPHX2MEN1 | |
| SCHEMBL27552260 | 0.85 | MEN1 (0.41) | SIGMAR1EPHX1EPHX2MEN1KMT2A | |
| SCHEMBL27572079 | 0.85 | SIGMAR1 (0.38) | SIGMAR1EPHX1CYP1A2EPHX2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298166-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | ABBVIE INC. | 2022-09-22 | — | — | US | disclosed |
| CN-1898317-B | Composition and method for controlling crystallization rate of polyolefin-based resin, resin composition, and resin molded article | NEW JAPAN CHEM CO LTD | 2010-11-24 | — | — | CN | disclosed |
| US-4459424-A | SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST | AKZONA INCORPORATED (US) | 1984-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298166-A1 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | TSLP, HRH4, IL4 | SIGMAR1 3172/4885SHBG 4744/4885KDM4E 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.